Aster DM Healthcare has reported a 10% YoY increase in revenue, reaching INR 1,197 Crs for Q2 FY26. Operating EBITDA also saw a significant rise of 13% YoY to INR 263 Crs. Aster MIMS Kasaragod commenced operations on October 2, 2025, further strengthening the company’s Kerala network. The company anticipates sustainable, long-term growth across key markets.
Key Financial Performance
Aster DM Healthcare demonstrated solid financial performance in Q2 FY26:
- Revenue increased by 10% YoY and 11% QoQ to INR 1,197 Crs.
- Operating EBITDA grew by 13% YoY and 22% QoQ to INR 263 Crs.
- Operating EBITDA Margins stood at 22.0%.
- Normalised PAT grew by 14% YoY and 23% QoQ to INR 110 Crs.
Operational Highlights
The company achieved strong operational milestones during the quarter:
- Kerala cluster showed significant turnaround.
- Inpatient volumes growing by 13% QoQ.
- MVT revenue surging 67% QoQ.
- Aster MIMS Kasaragod commenced operations on October 2, 2025.
India Performance
Overall Business: Double-digit YoY growth in Revenue & Operating EBITDA led by substantial recovery in Kerala, strong growth in international revenue and better case mix
- ARPP IP rose 10% YoY to INR 1,18,552 in Q2 FY26.
- CONGO mix increased by 240 bps to 51% in Q2FY26.
- Total patient volume grew by 15% QoQ.
- Occupancy grew to 64% in Q2 FY26 from 59% in Q1 FY26.
Cluster-wise Performance
- Occupancy: Kerala at 69%, K&M at 62% and A&T at 55%.
- Kerala total patient volume increased by 17% QoQ.
- Andhra & Telangana revenue grew 14% QoQ.
Merger Update
The company has completed the preferential allotment of ~3.6% stake to Blackstone and TPG. The company received no-objection letter from the Stock Exchanges for the merger and shall now approach National Company Law Tribunal (NCLT) for its approval.
QCIL Q2 FY26 Performance
QCIL has posted a strong performance in Q2 FY26, reporting a 15% year-on-year increase in revenue to INR 1,193 Cr. Operating EBITDA grew by 22% to INR 287 Cr.
Source: BSE
